An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada
BACKGROUND: Invasive aspergillosis (IA) is a serious fungal infection that affects immunocompromised patients. The Global Comparative Aspergillosis study demonstrated that voriconazole, a new broad-spectrum triazole, had better responses and improved survival compared with conventional amphotericin...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2004-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2004/183087 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560952733597696 |
|---|---|
| author | Coleman Rotstein Michel Laverdière Anne Marciniak Farzad Ali |
| author_facet | Coleman Rotstein Michel Laverdière Anne Marciniak Farzad Ali |
| author_sort | Coleman Rotstein |
| collection | DOAJ |
| description | BACKGROUND: Invasive aspergillosis (IA) is a serious fungal infection that affects immunocompromised patients. The Global Comparative Aspergillosis study demonstrated that voriconazole, a new broad-spectrum triazole, had better responses and improved survival compared with conventional amphotericin B deoxycholate (CAB) and other licensed antifungal therapy (OLAT) for the treatment of definite or probable aspergillosis. |
| format | Article |
| id | doaj-art-7cecb1793f3b484a8eafc5a5969794c4 |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2004-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-7cecb1793f3b484a8eafc5a5969794c42025-02-03T01:26:24ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322004-01-0115527728410.1155/2004/183087An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in CanadaColeman Rotstein0Michel Laverdière1Anne Marciniak2Farzad Ali3Division of Infectious Diseases, Department of Internal Medicine, McMaster University, Hamilton, Ontario, CanadaDepartment of Microbiology-Infectious Diseases, Hôpital Maisonneuve-Rosemont, Montréal, Quebec, CanadaPfizer Ltd, Sandwich, UKPfizer Canada, Kirkland, Quebec, CanadaBACKGROUND: Invasive aspergillosis (IA) is a serious fungal infection that affects immunocompromised patients. The Global Comparative Aspergillosis study demonstrated that voriconazole, a new broad-spectrum triazole, had better responses and improved survival compared with conventional amphotericin B deoxycholate (CAB) and other licensed antifungal therapy (OLAT) for the treatment of definite or probable aspergillosis.http://dx.doi.org/10.1155/2004/183087 |
| spellingShingle | Coleman Rotstein Michel Laverdière Anne Marciniak Farzad Ali An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada |
| title_full | An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada |
| title_fullStr | An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada |
| title_full_unstemmed | An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada |
| title_short | An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada |
| title_sort | economic evaluation of voriconazole versus amphotericin b for the treatment of invasive aspergillosis in canada |
| url | http://dx.doi.org/10.1155/2004/183087 |
| work_keys_str_mv | AT colemanrotstein aneconomicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada AT michellaverdiere aneconomicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada AT annemarciniak aneconomicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada AT farzadali aneconomicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada AT colemanrotstein economicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada AT michellaverdiere economicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada AT annemarciniak economicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada AT farzadali economicevaluationofvoriconazoleversusamphotericinbforthetreatmentofinvasiveaspergillosisincanada |